Home Featured Page 290

Featured

Latest

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery...

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Religious Use of Psychedelics in the United States

The Farmer and The Cowman Should Be Friends: Why the Pharmaceutical...

The Problem and Paradox of Bad Trips, Part 2

1...289290291...306 Page 290 of 306

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

DMT Pricing Guide

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery...

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Religious Use of Psychedelics in the United States

The Farmer and The Cowman Should Be Friends: Why the Pharmaceutical...

The Problem and Paradox of Bad Trips, Part 2

EDITOR PICKS

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY